SCHEMBL30775014

SCHEMBL30775014

Cc1ccc(-c2cc(C(=O)O)ccn2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 9/20 0.64
KDM2B Q8NHM5 1/20 0.64
KMO O15229 1/20 0.62
KDM5C P41229 5/20 0.57
KDM4E B2RXH2 4/20 0.57
KDM6B O15054 3/20 0.57
KDM2A Q9Y2K7 3/20 0.57
KDM3A Q9Y4C1 3/20 0.57
KDM5B Q9UGL1 7/20 0.56
KDM4A O75164 5/20 0.56
KDM5A P29375 4/20 0.56
KDM4B O94953 2/20 0.55
P4HA1 P13674 1/20 0.54
JMJD6 Q6NYC1 1/20 0.54
CTRC Q99895 1/20 0.54
KDM1A O60341 2/20 0.53
HDAC1 Q13547 2/20 0.53
LOXL2 Q9Y4K0 1/20 0.53
HDAC6 Q9UBN7 1/20 0.51
ALDH1A1 P00352 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nitrous Acid SCHEMBL29134645 0.94 KDM4C (0.59) KDM4CKDM2BKMOKDM5CKDM4E
SCHEMBL4894953 0.85 LOXL2 (0.56) KDM4CKDM2BKMOKDM4EKDM5B
SCHEMBL4895581 0.85 LOXL2 (0.56) KDM4CKDM2BKMOKDM4EKDM5B
SCHEMBL2556149 0.85 KMO (0.60) KDM4CKDM2BKMOKDM5CKDM4E
SCHEMBL29932995 0.85 MAP4K4 (0.54) KDM4CKDM2BKMOKDM5CKDM5B
SCHEMBL29541336 0.84 KDM4C (0.71) KDM4CKMOKDM5CKDM4EKDM6B
SCHEMBL648273 0.84 KDM4C (0.71) KDM4CKMOKDM5CKDM4EKDM6B
SCHEMBL23303939 0.83 KMO (0.67) KDM4CKDM2BKMOKDM5CKDM4E
SCHEMBL30318846 0.83 KMO (0.67) KDM4CKDM2BKMOKDM5CKDM4E
SCHEMBL19433797 0.83 LOXL2 (0.60) KDM4CKDM2BKMOKDM4EKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727549-A2 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS University of Georgia Research Foundation, Inc. (US) 2026-04-22 EP disclosed
US-20260097046-A1 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS UNIV GEORGIA (US) 2026-04-09 US disclosed
WO-2024258900-A2 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-12-19 WO disclosed
CN-117343002-A Synthesis method of beta-cyanoalkyl pyridine compound 西南医科大学 2024-01-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097046-A1 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS SUB1, PFN1, HCCS KDM4C 2754/4885KDM2B 3244/4885KMO 2781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.